IL6 and rheumatoid arthritis: The treatment of RA has advanced significantly by targeting key molecules including tumor necrosis factor alpha (TNF-α) or interleukin 6 (IL-6) using a group of drugs called biological disease-modifying anti-rheumatic drug (bDMARDs) [4–6].